Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection
Publication Type:
Journal Article
Authors:
Osinusi, A.;
Townsend, K.;
Kohli, A.;
Nelson, A.;
Seamon, C.;
Meissner, E.G.;
Bon, D.;
Silk, R.;
Gross, C.;
Price, A.;
Sajadi, M.;
Sidharthan, S.;
Sims, Z.;
Herrmann, E.;
Hogan, J.;
Teferi, G.;
Talwani, R.;
Proschan, M.;
Jenkins, V.;
Kleiner, D.E.;
Wood, B.J.;
Subramanian, G.M.;
Pang, P.S.;
J G McHutchison;
Polis, M.A.;
Fauci, A.S.;
Masur, H.;
Kottilil, S.Source:
JAMA, Volume 313, Issue 12, p.1232-1239 (2015)
Keywords:
adherence,
Antiretroviral,
Antiretroviral Therapy,
Baltimore,
California,
Cities,
co-infected,
co-infection,
coinfection,
Counseling,
deep sequencing,
Disease,
Family,
Genotype,
genotype 1,
Germany,
HCV,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hiv,
HIV RNA,
Human,
immunology,
Infection,
interferon,
interventions,
Laboratories,
Maryland,
Medicine,
microbiology,
Mutation,
NS5A inhibitor,
pathology,
Patients,
Plasma,
Radiology,
Research,
resistance,
Rna,
Safety,
sofosbuvir,
South Carolina,
sustained virologic response,
SVR,
therapy,
treatment,
Universities,
virology,
Washington
